There is a new morning after pill that prevents a fertilized embryo from attaching to the mother’s womb, an abortifacient that pro-deathers want made available over-the-counter. What I’d like to concentrate on, though, is this reporter’s framing of the issue. Consider especially this last sentence:
A French drug company is seeking to offer American women something their European counterparts already have: a pill that works long after “the morning after.”
The drug, dubbed ella, would be sold as a contraceptive — one that could prevent pregnancy for as many as five days after unprotected sex. But the new drug is a close chemical relative of the abortion pill RU-486, raising the possibility that it could also induce abortion by making the womb inhospitable for an embryo.
The controversy sparked by that ambiguity promises to overshadow the work of a federal panel that will convene next week to consider endorsing the drug. The last time the Food and Drug Administration vetted an emergency contraceptive — Plan B, the so-called morning-after pill — the decision was mired in debate over such fundamental questions as when life begins and the distinction between preventing and terminating a pregnancy. Ella is raising many of those same politically charged questions — but more sharply, testing the Obama administration’s pledge to keep ideology from influencing scientific decisions.